MRNS Live signals | Maximize Profits with Getagraph.com

SELL 101988 min ago

@ $10.08

Issued: 14 Feb 2024 @ 09:30

Return: -85.71%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: 3.70 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders...

Stats
Today's Volume	1.51M
Average Volume	1.72M
Market Cap	78.69M
EPS	$0 ( 2024-03-05 )
Next earnings date	( $-0.680 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.550
ATR14	$0.00500 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Braunstein Scott	Buy	50 000	Common Stock
2024-03-27	Braunstein Scott	Sell	50 000	Stock Option (Right to Buy)
2024-02-20	Shafer Christina	Sell	2 153	Common Stock
2024-02-20	Manning Martha E	Sell	1 894	Common Stock
2024-02-16	Hulihan Joseph	Sell	2 814	Common Stock

INSIDER POWER
87.43
Last 96 transactions
Buy: 2 669 285 \| Sell: 293 774

Volume Correlation

Long: 0.73 (moderate)

Short: 0.86 (strong)

Signal:(73.775) Same movement expected

Marinus Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Marinus Pharmaceuticals Correlation - Currency/Commodity

0.15
( neutral )

-0.12
( neutral )

0.00
( neutral )

0.25
( neutral )

0.00
( neutral )

0.06
( neutral )

Marinus Pharmaceuticals Financials

Annual	2023
Revenue:	$30.99M
Gross Profit:	$28.50M (91.98 %)
EPS:	$-2.63

Q4	2023
Revenue:	$7.19M
Gross Profit:	$6.18M (85.92 %)
EPS:	$-0.740

Q3	2023
Revenue:	$7.34M
Gross Profit:	$6.88M (93.80 %)
EPS:	$-0.610

Q2	2023
Revenue:	$6.08M
Gross Profit:	$5.70M (93.65 %)
EPS:	$-0.610

Financial Reports:

No articles found.

Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.